Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14297MR)

This product GTTS-WQ14297MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14297MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14715MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ12772MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ14696MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ5608MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ2272MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ14362MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ15867MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ13574MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW